Adamas Pharmaceuticals, a specialty pharmaceutical company focused on enhancing approved drugs for chronic disorders of the central nervous system, priced its IPO at $16 per share (the low end of its $16 to $18 range) and went public, trading on the NASDAQ under the symbol ADMS. The company raised $48 million by offering 3 million shares. In 2009, Adamas raised $40 million of Series D funding at a valuation of $197 million. Its stockholders include Mohr Davidow Ventures (30.9% pre-IPO stake), Aeris Capital (16%), DAG Ventures (12%) and Northgate Capital (6.4%), among others. Adamas finished its first day of trading at $14.01.